Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income

Abstract

Objectives Testing and treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are highly effective, high-impact interventions. This article aims to estimate the cost-effectiveness of scaling up these interventions by scenarios, regions, and income groups. Methods We modeled costs and impacts of hepatitis elimination in 67 low- and middle-income countries from 2016 to 2030. Costs included testing and treatment commodities, healthcare consultations, and future savings from cirrhosis and hepatocellular carcinomas averted. We modeled disease progression to estimate disability-adjusted life-years (DALYs) averted. We estimated incremental cost-effectiveness ratios (ICERs) by regions and World Bank income groups, according to 3 scenarios: flatline (status quo), progress (testing/treatment according to World Health Organization guidelines), and ambitious (elimination). Results Compared with no action, current levels of testing and treatment had an ICER of $807/DALY for HBV and –$62/DALY (cost-saving) for HCV. Scaling up to progress scenario, both interventions had ICERs less than the average gross domestic product/capita of countries (HBV: $532/DALY; HCV: $613/DALY). Scaling up from flatline to elimination led to higher ICERs across countries (HBV: $927/DALY; HCV: $2528/DALY, respectively) that remained lower than the average gross domestic product/capita. Sensitivity analysis indicated discount rates and commodity costs were main factors driving results. Conclusions Scaling up testing and treatment for HBV and HCV infection as per World Health Organization guidelines is a cost-effective intervention. Elimination leads to a much larger impact though ICERs are higher. Price reduction strategies are needed to achieve elimination given the substantial budget impact at current commodity prices.

Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia

“…Costs were estimated from a health care provider perspective in 2020 US dollars (US$). Costing data were collected in The Gambia or derived from a previous global study [ 10 ] and included active case finding using a rapid diagnostic test, diagnostic tests involved in clinical assessments, and antiviral treatment using TDF ( Table 2 , Section 2D in the Online Supplementary Document ). As access to medical care for advanced liver disease is very limited in The Gambia, we made the conservative assumption that the treatment programme would not save costs associated with management of cirrhosis or HCC [ 6 ].…”

The global fight against hepatitis B is benefitting some parts of the world more than others

“…In an analysis 4 that included 67 countries, in which 230 million people live with hepatitis B, Hutin, Toy and their colleagues estimated that testing 5.5 billion people and treating 32 million individuals who have the virus would eliminate it as a public-health problem and avert 3.4 million deaths by 2030 (see 'Big investments needed'). That amount of testing and treatment would cost US$927 for every life year saved 5 . "Progress is affordable, reasonable and highly cost effective," Hutin says.…”

Refocusing on sexually transmitted infections (STIs) to improve reproductive health: a call to further action

“…Despite this, there is a seeming reluctance on the part of many governments to fund and execute STI control strategies. These issues have been given lower priority in the face of competing demands for scarce resources [ 23 ].…”